Treatment of heart failure with preserved ejection fraction: Reflections on its treatment with an aldosterone antagonist

JAMA Cardiology

Volumn 1, Issue 1, 2016, Pages 7-8

  Pfeffer, Marc A ^a   Braunwald, Eugene ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; MINERALOCORTICOID ANTAGONIST; PLACEBO; SPIRONOLACTONE;

BLOOD PRESSURE MONITORING; CARDIAC MUSCLE CELL; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIASTOLIC DYSFUNCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; EXTRACELLULAR MATRIX; FIBROSING ALVEOLITIS; HEART ARREST; HEART DEATH; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE MASS; HEART MUSCLE COMPLIANCE; HEART MUSCLE FIBROSIS; HEART MUSCLE RELAXATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PULMONARY HYPERTENSION; SHORT SURVEY; HEART FAILURE; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PHYSIOLOGY;

HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; STROKE VOLUME;

EID: 84994058196     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2015.0356     Document Type: Short Survey

References (10)

1. Borlaug BA, Nishimura RA, Sorajja P, Lam CSP, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010; 3(5):588-595.
2. Shah AM, Claggett B, Sweitzer NK, et al. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail. 2014; 7(5):740-751.
3. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993; 25(5): 563-575.
4. Pitt B, Zannad F, Remme WJ, et al.; Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341(10):709-717.
5. Pitt B, Remme W, Zannad F, et al.; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348(14): 1309-1321.
6. Zannad F, McMurray JJV, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364(1):11-21.
7. Zannad F, Alla F, Dousset B, Perez A, Pitt B; Rales Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation. 2000; 102(22):2700-2706.
8. Pandey A, Garg S, Matulevicius SA, et al. Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: a meta-analysis and systematic review. J Am Heart Assoc. 2015; 4(10): e002137.
9. Pitt B, Pfeffer MA, Assmann SF, et al.; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-1392.
10. Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circulation. 2015; 131(1):34-42.